Ptc Therapeutics (PTCT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.92
- EPS estimate
- $0.24
- EPS surprise
- +289.34%
- Revenue surprise
- +20.72%
- Revenue
- $360.5M
- Revenue estimate
- $298.6M
- Reported
- Jul 30, 2026
PTC Therapeutics reported Q2 2026 results on July 30, 2026. EPS of $0.92 was well above the $0.24 estimate, a 289.34% beat. Revenue reached $360.5 million against a $298.6 million consensus, 20.72% higher. A year earlier, in Q2 2025, the company lost $0.83 per share on revenue of $178.9 million, so revenue roughly doubled.
For most of the table, the company ran at a loss. Every quarter from Q3 2021 through Q4 2024 was a loss, the deepest at $2.66 per share in Q2 2023. Annual losses were $7.79 per share in 2022, $8.36 in 2023 and $4.73 in 2024. Q1 2025 stands apart, with EPS of $10.04 on revenue of $1.2 billion, both far above any other quarter shown. That quarter lifted 2025 to full-year EPS of $7.74, despite losses in Q2 and Q4, including $1.67 per share in Q4 2025. The company beat the EPS estimate in 7 of the last 20 quarters.
Q3 results came between October 26 and November 7 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the Q2 profit carries into the following quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $0.24 | $0.92 | +289.34% | $360.5M | SEC |
| Q1 2026 | May 7, 2026 | −$0.47 | −$0.03 | +93.64% | $272.6M | SEC |
| Q4 2025 | Feb 19, 2026 | $0.10 | −$1.67 | −1721.36% | $164.7M | SEC |
| Q3 2025 | Nov 4, 2025 | −$1.13 | $0.20 | +117.65% | $211.0M | SEC |
| Q2 2025 | Aug 7, 2025 | −$1.02 | −$0.83 | +18.74% | $178.9M | SEC |
| Q1 2025 | May 6, 2025 | −$1.01 | $10.04 | +1096.23% | $1.2B | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.54 | −$0.85 | −57.32% | $213.2M | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.52 | −$1.39 | +8.61% | $196.8M | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.12 | −$1.29 | −15.19% | $186.7M | SEC |
| Q1 2024 | Apr 25, 2024 | −$1.27 | −$1.20 | +5.86% | $210.1M | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.14 | −$2.06 | −1390.59% | $307.1M | SEC |
| Q3 2023 | Oct 26, 2023 | −$1.07 | −$1.76 | −65.26% | $196.6M | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.62 | −$2.66 | −64.07% | $213.8M | SEC |
| Q1 2023 | Apr 27, 2023 | −$1.53 | −$1.88 | −22.53% | $220.4M | SEC |
| Q4 2022 | Feb 21, 2023 | −$1.59 | −$2.35 | −48.05% | $167.4M | SEC |
| Q3 2022 | Oct 27, 2022 | −$1.28 | −$1.53 | −19.23% | $217.1M | SEC |
| Q2 2022 | Aug 4, 2022 | −$1.37 | −$2.13 | −55.68% | $165.5M | SEC |
| Q1 2022 | May 3, 2022 | −$1.51 | −$1.78 | −18.05% | $148.7M | SEC |
| Q4 2021 | Feb 22, 2022 | −$1.68 | −$2.03 | −20.89% | $165.2M | SEC |
| Q3 2021 | Oct 28, 2021 | −$1.66 | −$1.89 | −14.08% | $138.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Ptc Therapeutics (PTCT) last report earnings?
Ptc Therapeutics last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did PTCT beat earnings estimates?
Yes. Ptc Therapeutics reported EPS of $0.92 for Q2 2026 against a $0.24 estimate — a 289.34% beat.
How much revenue did PTCT report last quarter?
Ptc Therapeutics reported $360.5M in revenue for Q2 2026, against a consensus estimate of $298.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.